Patents Represented by Attorney, Agent or Law Firm George E. Heibel
  • Process for the preparation of rosuvastatin
    Patent number: 7566782
    Abstract: The present invention relates to a process for the preparation of rosuvastatin calcium, a promising new HMG-CoA reductase inhibitor.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: July 28, 2009
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Yatendra Kumar, Hashim Nizar Poovanathil Nagoor Meeran, Shantanu De, Mohammad Rafeeq, Swargam Sathyanarayana
  • Azabicyclo derivatives as muscarinic receptor antagonists
    Patent number: 7544708
    Abstract: This invention generally relates to muscarinic receptor antagonists which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Specifically, the invention relates to derivatives of azabicyclo compounds, including, for example, 6-substituted azabicyclo[3.1.0] hexanes, and 2,4,6-trisubstituted derivatives. The invention also relates to pharmaceutical compositions containing the compounds and the methods of treating the diseases mediated through muscarinic receptors.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: June 9, 2009
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Mohammad Salman, Anita Mehta, Pakala Kumara Savithru Sarma, Shankar Jayram Shetty, Sankaranarayanan Dharmarajan, Naresh Kumar, Arundutt Vishwanatham Silamkoti, Anita Chugh
  • Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
    Patent number: 7288562
    Abstract: This invention generally relates to the derivatives of novel 3,6 disubstituted azabicyclo[3.1.0] hexane's. The compounds of this invention are MUSCARINIC receptor antagonists which are useful, inter-ail for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through MUSCARINIC receptors. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through MUSCARINIC receptors.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: October 30, 2007
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Jang Bahadur Gupta
  • Process for the preparation of highly pure crystalline (R,S)—cefuroxime axetil
    Patent number: 6833452
    Abstract: A process for the preparation of highly pure crystalline form of cefuroxime-1-acetoxyethyl ester (cefuroxime axetil) from cefuroxime by reacting an amine salt of cefuroxime with an esterifying reagent.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: December 21, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Om Dutt Tyagi, Gyan Chand Yadav, Vijay Kumar Handa
  • Process for the preparation of tolterodine
    Patent number: 6822119
    Abstract: The present invention relates to a cost effective and industrially advantageous process for the preparation of tolterodine and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 18, 2004
    Date of Patent: November 23, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Yatendra Kumar, Mohan Prasad, Praveen Kumar Neela, Satyananda Misra
  • Process for the synthesis of n-(5-methylnicontinoyl)-4 hydroxypiperidine, a key intermediate of rupatadine
    Patent number: 6803468
    Abstract: The present invention relates to an improved and industrially advantageous process for the preparation of N-(5-methylnicotinoyl)-4-hydroxypiperidine of Formula I, as shown in the accompanied drawings. This compound is a key intermediate for the synthesis of rupatadine, a potent dual antagonist of histamine and platelet-activating factor (PAF).
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: October 12, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Yatendra Kumar, Mohan Prasad, Shallendra Kumar Singh
  • Oxazolidinone derivatives as antimicrobials
    Patent number: 6734307
    Abstract: The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: May 11, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Arora K. Sudershan, Biswajit Das, Abhijit Ray, Sonali Rudra, Ashok Rattan
  • Azole compounds as anti-fungal agents
    Patent number: 6710049
    Abstract: The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared with presently available agents in this class and the processes for the preparation thereof. This invention also relates to pharmaceutical preparations containing the compounds of the present invention and their use in treating and/or preventing the fungal infections in mammals, preferably humans.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: March 23, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Mohammed Salman, Rita Katoch, Ashwani Kumar Verma, Jitendra Sattigeri, Ashok Rattan
  • Synthesis of 3-ethoxy-4-ethoxycarbonyl phenyl acetic acid, a key acid synthon of repaglinide
    Patent number: 6686497
    Abstract: The present invention relates to a new and industrially advantageous process for the preparation of 3-ethoxy-4-ethoxy-carbonyl-phenyl acetic acid. This compound is a key intermediate for the synthesis of Repaglinide, an oral hypoglycemic agent.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: February 3, 2004
    Assignee: Banbaxy Laboratories Limited
    Inventors: Mohammad Salman, J. Suresh Babu, Purna C. Ray, Sujay Biswas, Naresh Kumar
  • Process for the preparation of fluoxetine hydrochloride
    Patent number: 6677485
    Abstract: An improved and industrially advantageous process for the preparation of the antidepressant fluoxetine and its pharmaceutically acceptable salts, preferably hydrochloride.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: January 13, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Naresh Kumar, Bakthavathsalan Vijayaraghavan, Kinali Venkata Ramana, Swargam Sathyanarayana
  • Controlled release formulation
    Patent number: 6673369
    Abstract: The present invention relates to a controlled release pharmaceutical composition comprising amounts ranging from about 0.1 to about 4.5% w/w, of one or more of rate controlling cellulosic ether polymers.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: January 6, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Ashok Rampal, Rajeev S. Raghuvanshi, Manoj Kumar
  • Azole compounds as therapeutic agents for fungal infections
    Patent number: 6670363
    Abstract: The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared to known compounds such as fluconazole and itraconazole and the processes for the preparation thereof. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing fungal infections in mammals, preferably humans.
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: December 30, 2003
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Ashwani Kumar Verma, Sudershan K. Arora, Jasbir Singh Arora, Ashok Rattan
  • Derivatives of monosaccharides as cell adhesion inhibitors
    Patent number: 6590085
    Abstract: This invention relates generally to compounds and processes for synthesizing derivatives of 2-3-O-isopropylidene-&agr;-L-xylo-2-hexulofuranosonic acid. The compounds of this invention are useful, inter-alia, for the inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases, such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection and psoriasis. This invention also relates to pharmacological compositions containing derivatives of 2-3-O-isopropylidene-&agr;-L-xylo-2-hexulofuranosonic acid and the methods of treating such pathologies as listed above.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: July 8, 2003
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Sudershan K Arora, Nawal Kishore, Jang Bahadur Gupta, Vishwas D Joshi
  • Extended release formulation of etodolac
    Patent number: 6586005
    Abstract: A sustained release formulation of etodolac for once daily administration is described.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: July 1, 2003
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Rajeev S. Raghuvanshi, Ashok Rampal, Himadri Sen